Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 10/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19666518 | 1.00 | SYK (0.47) | SYKMAPK8MAPK9MAPK10JUN | |
| SCHEMBL19666524 | 0.94 | SYK (0.50) | SYKMAPK8MAPK9MAPK10BTK | |
| SCHEMBL19666526 | 0.94 | SYK (0.50) | SYKMAPK8MAPK9MAPK10BTK | |
| SCHEMBL29717674 | 0.86 | MAPK8 (0.49) | SYKMAPK8MAPK9 | |
| SCHEMBL19666279 | 0.86 | MAPK8 (0.49) | SYKMAPK8MAPK9 | |
| SCHEMBL19666631 | 0.86 | MAPK8 (0.49) | SYKMAPK8MAPK9 | |
| SCHEMBL19666278 | 0.86 | MAPK8 (0.49) | SYKMAPK8MAPK9 | |
| SCHEMBL19666589 | 0.86 | SYK (0.43) | SYKMAPK8MAPK9MAPK10JUN | |
| SCHEMBL19666587 | 0.86 | SYK (0.43) | SYKMAPK8MAPK9MAPK10JUN | |
| SCHEMBL19666569 | 0.84 | SYK (0.45) | SYKMAPK8MAPK9BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | TPMT, TYMP, ATIC | SYK 4069/4885MAPK8 1870/4885MAPK9 2986/4885 |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | SYK 4069/4885MAPK8 1870/4885MAPK9 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.